Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice

Journal of Immunology

Volumn 187, Issue 4, 2011, Pages 1957-1969

  Bento, Allisson Freire ^a   Claudino, Rafaela Franco ^a   Dutra, Rafael Cypriano ^a   Marcon, Rodrigo ^a   Calixto, João B ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXY DOCOSAHEXAENOIC ACID; ACETYLSALICYLIC ACID; CXCL1 CHEMOKINE; CYTOKINE; DEXTRAN SULFATE; FORMYLPEPTIDE RECEPTOR LIKE 1; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OMEGA 3 FATTY ACID; RESOLVIN D1; RESOLVIN D2; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL STIMULATION; COLITIS; COLON INJURY; CONTROLLED STUDY; DISEASE ACTIVITY; EXPERIMENTAL MOUSE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ASPIRIN; BONE MARROW CELLS; CELL ADHESION MOLECULES; COLITIS; CYTOKINES; DEXTRAN SULFATE; DOCOSAHEXAENOIC ACIDS; GENE EXPRESSION REGULATION; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; RECEPTORS, FORMYL PEPTIDE; RNA, MESSENGER; TRINITROBENZENES; WATER POLLUTANTS, CHEMICAL;

EID: 80051922251     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101305     Document Type: Article

References (61)

1. Spite, M., and C. N. Serhan. 2010. Novel lipid mediators promote resolution of acute inflammation: Impact of aspirin and statins. Circ. Res. 107: 1170-1184.
2. Serhan, C. N., C. B. Clish, J. Brannon, S. P. Colgan, N. Chiang, and K. Gronert. 2000. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from v-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192: 1197-1204.
3. Serhan, C. N., and J. Savill. 2005. Resolution of inflammation: The beginning programs the end. Nat. Immunol. 6: 1191-1197. (Pubitemid 43045627)
4. Schwab, J. M., and C. N. Serhan. 2006. Lipoxins and new lipid mediators in the resolution of inflammation. Curr. Opin. Pharmacol. 6: 414-420.
5. Teitelbaum, J. E., and W. Allan Walker. 2001. Review: The role of ω 3 fatty acids in intestinal inflammation. J. Nutr. Biochem. 12: 21-32. (Pubitemid 32120193)
6. Kremer, J. M. 2000. n-3 Fatty acid supplements in rheumatoid arthritis. Am. J. Clin. Nutr. 71(1, Suppl)349S-351S. (Pubitemid 30046140)
7. Ishida, T., M. Yoshida, M. Arita, Y. Nishitani, S. Nishiumi, A. Masuda, S. Mizuno, T. Takagawa, Y. Morita, H. Kutsumi, et al. 2010. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis. 16: 87-95.
8. Calder, P. C. 2002. Dietary modification of inflammation with lipids. Proc. Nutr. Soc. 61: 345-358. (Pubitemid 34982924)
9. Serhan, C. N. 2007. Resolution phase of inflammation: Novel endogenous antiinflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25: 101-137. (Pubitemid 46697904)
10. Arita, M., F. Bianchini, J. Aliberti, A. Sher, N. Chiang, S. Hong, R. Yang, N. A. Petasis, and C. N. Serhan. 2005. Stereochemical assignment, antiinflammatory properties, and receptor for the v-3 lipid mediator resolvin E1. J. Exp. Med. 201: 713-722. (Pubitemid 40395117)
11. Serhan, C. N., S. Hong, K. Gronert, S. P. Colgan, P. R. Devchand, G. Mirick, and R. L. Moussignac. 2002. Resolvins: A family of bioactive products of v-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196: 1025-1037. (Pubitemid 35231761)
12. Sun, Y. P., S. F. Oh, J. Uddin, R. Yang, K. Gotlinger, E. Campbell, S. P. Colgan, N. A. Petasis, and C. N. Serhan. 2007. Resolvin D1 and its aspirin-triggered 17R epimer: Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem. 282: 9323-9334. (Pubitemid 47104612)
13. Hong, S., K. Gronert, P. R. Devchand, R. L. Moussignac, and C. N. Serhan. 2003. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells: Autacoids in anti-inflammation. J. Biol. Chem. 278: 14677-14687. (Pubitemid 36799790)
14. Marcheselli, V. L., S. Hong, W. J. Lukiw, X. H. Tian, K. Gronert, A. Musto, M. Hardy, J. M. Gimenez, N. Chiang, C. N. Serhan, and N. G. Bazan. 2003. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278: 43807-43817. (Pubitemid 37346009)
15. Xu, Z. Z., L. Zhang, T. Liu, J. Y. Park, T. Berta, R. Yang, C. N. Serhan, and R. R. Ji. 2010. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16: 592-597, 1p following 597.
16. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533. (Pubitemid 37328672)
17. Baumgart, D. C., and S. R. Carding. 2007. Inflammatory bowel disease: Cause and immunobiology. Lancet 369: 1627-1640. (Pubitemid 46722636)
18. Podolsky, D. K. 2002. The current future understanding of inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 16: 933-943.
19. McGuckin, M. A., R. Eri, L. A. Simms, T. H. Florin, and G. Radford-Smith. 2009. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 15: 100-113.
20. Cho, J. Y., S. G. Chi, and H. S. Chun. 2011. Oral administration of docosahexaenoic acid attenuates colitis induced by dextran sulfate sodium in mice. Mol. Nutr. Food Res. 55: 239-246.
21. Almallah, Y. Z., S. W. Ewen, A. El-Tahir, N. A. Mowat, P. W. Brunt, T. S. Sinclair, S. D. Heys, and O. Eremin. 2000. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): The mucosal effect in situ. J. Clin. Immunol. 20: 68-76. (Pubitemid 30210109)
22. Camuesco, D., M. Comalada, A. Concha, A. Nieto, S. Sierra, J. Xaus, A. Zarzuelo, and J. Gálvez. 2006. Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis. Clin. Nutr. 25: 466-476. (Pubitemid 44182761)
23. Camuesco, D., J. Gálvez, A. Nieto, M. Comalada, M. E. Rodríguez-Cabezas, A. Concha, J. Xaus, and A. Zarzuelo. 2005. Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J. Nutr. 135: 687-694. (Pubitemid 40464089)
24. Calder, P. C. 2008. Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol. Nutr. Food Res. 52: 885-897.
25. Arita, M., M. Yoshida, S. Hong, E. Tjonahen, J. N. Glickman, N. A. Petasis, R. S. Blumberg, and C. N. Serhan. 2005. Resolvin E1, an endogenous lipid mediator derived from ω-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA 102: 7671-7676. (Pubitemid 40741029)
26. Ghia, J. E., P. Blennerhassett, and S. M. Collins. 2008. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J. Clin. Invest. 118: 2209-2218. (Pubitemid 351872339)
27. Cooper, H. S., S. N. Murthy, R. S. Shah, and D. J. Sedergran. 1993. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69: 238-249.
28. Kimball, E. S., N. H. Wallace, C. R. Schneider, M. R. D'Andrea, and P. J. Hornby. 2004. Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol. Motil. 16: 811-818. (Pubitemid 40022788)
29. Bento, A. F., D. F. Leite, R. F. Claudino, D. B. Hara, P. C. Leal, and J. B. Calixto. 2008. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J. Leukoc. Biol. 84: 1213-1221.
30. Hara, D. B., E. S. Fernandes, M. M. Campos, and J. B. Calixto. 2007. Pharmacological and biochemical characterization of bradykinin B2 receptors in the mouse colon: Influence of the TNBS-induced colitis. Regul. Pept. 141: 25-34. (Pubitemid 46482692)
31. Wallace, J. L., W. K. MacNaughton, G. P. Morris, and P. L. Beck. 1989. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96: 29-36. (Pubitemid 19046263)
32. Souza, D. G., C. T. Fagundes, F. A. Amaral, D. Cisalpino, L. P. Sousa, A. T. Vieira, V. Pinho, J. R. Nicoli, L. Q. Vieira, I. M. Fierro, and M. M. Teixeira. 2007. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J. Immunol. 179: 8533-8543.
33. Spite, M., L. V. Norling, L. Summers, R. Yang, D. Cooper, N. A. Petasis, R. J. Flower, M. Perretti, and C. N. Serhan. 2009. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461: 1287-1291.
34. Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
35. Stanley, E. R. 1997. Murine bone marrow-derived macrophages. Methods Mol. Biol. 75: 301-304.
36. Vitor, C. E., C. P. Figueiredo, D. B. Hara, A. F. Bento, T. L. Mazzuco, and J. B. Calixto. 2009. Therapeutic action and underlying mechanisms of a combination of two pentacyclic triterpenes, α- and β-amyrin, in a mouse model of colitis. Br. J. Pharmacol. 157: 1034-1044.
37. Barker, J. N., M. L. Jones, C. L. Swenson, V. Sarma, R. S. Mitra, P. A. Ward, K. J. Johnson, J. C. Fantone, V. M. Dixit, and B. J. Nickoloff. 1991. Monocyte chemotaxis and activating factor production by keratinocytes in response to IFNγ. J. Immunol. 146: 1192-1197.
38. Yoshida, M., and M. A. Gimbrone Jr. 1997. Novel roles for E-selectin in endothelial-leukocyte adhesion. Ann. N.Y. Acad. Sci. 811: 493-497. (Pubitemid 27308357)
39. Krishnamoorthy, S., A. Recchiuti, N. Chiang, S. Yacoubian, C. H. Lee, R. Yang, N. A. Petasis, and C. N. Serhan. 2010. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc. Natl. Acad. Sci. USA 107: 1660-1665.
40. Gewirtz, A. T., L. S. Collier-Hyams, A. N. Young, T. Kucharzik, W. J. Guilford, J. F. Parkinson, I. R. Williams, A. S. Neish, and J. L. Madara. 2002. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J. Immunol. 168: 5260-5267. (Pubitemid 34495994)
41. Okayasu, I., S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702. (Pubitemid 20069706)
42. Cominelli, F., C. C. Nast, B. D. Clark, R. Schindler, R. Lierena, V. E. Eysselein, R. C. Thompson, and C. A. Dinarello. 1990. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J. Clin. Invest. 86: 972-980. (Pubitemid 20327390)
43. Neurath, M. F., I. Fuss, M. Pasparakis, L. Alexopoulou, S. Haralambous, K. H. Meyer zum Büschenfelde, W. Strober, and G. Kollias. 1997. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. 27: 1743-1750. (Pubitemid 27302858)
44. Rutgeerts, P., G. Van Assche, and S. Vermeire. 2004. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 126: 1593-1610. (Pubitemid 38649876)
45. Essani, N. A., M. A. Fisher, A. Farhood, A. M. Manning, C. W. Smith, and H. Jaeschke. 1995. Cytokine-induced upregulation of hepatic intercellular adhesion molecule-1 messenger RNA expression and its role in the pathophysiology of murine endotoxin shock and acute liver failure. Hepatology 21: 1632-1639.
46. Stocker, C. J., K. L. Sugars, O. A. Harari, R. C. Landis, B. J. Morley, and D. O. Haskard. 2000. TNF-α, IL-4, and IFN-γ regulate differential expression of P- and E-selectin expression by porcine aortic endothelial cells. J. Immunol. 164: 3309-3315. (Pubitemid 30148995)
47. Danese, S., S. Semeraro, M. Marini, I. Roberto, A. Armuzzi, A. Papa, and A. Gasbarrini. 2005. Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation. Dig. Liver Dis. 37: 811-818. (Pubitemid 44356115)
48. Sans, M., J. Panés, E. Ardite, J. I. Elizalde, Y. Arce, M. Elena, A. Palacín, J. C. Fernández-Checa, D. C. Anderson, R. Lobb, and J. M. Piqué. 1999. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 116: 874-883. (Pubitemid 29153535)
49. Soriano, A., A. Salas, A. Salas, M. Sans, M. Gironella, M. Elena, D. C. Anderson, J. M. Piqué, and J. Panés. 2000. VCAM-1, but not ICAM-1 or MAdCAM-1, immunoblockade ameliorates DSS-induced colitis in mice. Lab. Invest. 80: 1541-1551.
50. Tian, H., Y. Lu, A. M. Sherwood, D. Hongqian, and S. Hong. 2009. Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: Biosynthesis and mechanisms of anti-inflammatory actions. Invest. Ophthalmol. Vis. Sci. 50: 3613-3620.
51. Khalfoun, B., G. Thibault, P. Bardos, and Y. Lebranchu. 1996. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human lymphocyte-endothelial cell adhesion. Transplantation 62: 1649-1657. (Pubitemid 27009925)
52. Rahman, M. M., A. Bhattacharya, and G. Fernandes. 2008. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J. Cell. Physiol. 214: 201-209. (Pubitemid 350225482)
53. Lima-Garcia, J., R. Dutra, K. da Silva, E. Motta, M. Campos, and J. Calixto. 2011. The precursor of resolvin D series and aspirin-triggered resolvin D1 display anti-hyperalgesic properties in adjuvant-induced arthritis in rats. Br. J. Pharmacol. .
54. Hanauer, S. B. 2006. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12(Suppl. 1): S3-S9. (Pubitemid 43068428)
55. Rafi, M. M., P. N. Yadav, and A. O. Rossi. 2007. Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-κB. Mol. Nutr. Food Res. 51: 587-593. (Pubitemid 47083696)
56. Sklyarov, A. Y., N. B. Panasyuk, and I. S. Fomenko. 2011. Role of nitric oxidesynthase and cyclooxygenase/lipooxygenase systems in development of experimental ulcerative colitis. J. Physiol. Pharmacol. 62: 65-73.
57. Hirafuji, M., T. Machida, M. Tsunoda, A. Miyamoto, and M. Minami. 2002. Docosahexaenoic acid potentiates interleukin-1β induction of nitric oxide synthase through mechanism involving p44/42 MAPK activation in rat vascular smooth muscle cells. Br. J. Pharmacol. 136: 613-619. (Pubitemid 34717706)
58. Satake, K., Y. Matsuyama, M. Kamiya, H. Kawakami, H. Iwata, K. Adachi, and K. Kiuchi. 2000. Nitric oxide via macrophage iNOS induces apoptosis following traumatic spinal cord injury. Brain Res. Mol. Brain Res. 85: 114-122. (Pubitemid 32056242)
59. Marriott, H. M., F. Ali, R. C. Read, T. J. Mitchell, M. K. Whyte, and D. H. Dockrell. 2004. Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection. FASEB J. 18: 1126-1128. (Pubitemid 39561545)
60. Wanga, B., X. Gong, J.-y. Wan, L. Zhang, Z. Zhang, H.-z. Li, and S. Min. 2011. Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm. Pharmacol. Ther. 24: 434-441.
61. Hudert, C. A., K. H. Weylandt, Y. Lu, J. Wang, S. Hong, A. Dignass, C. N. Serhan, and J. X. Kang. 2006. Transgenic mice rich in endogenous v-3 fatty acids are protected from colitis. Proc. Natl. Acad. Sci. USA 103: 11276-11281. (Pubitemid 44156509)